What the trials measured
Kisspeptin benefits: what changed in short trials.
Doctors checked blood hormones, egg growth, and sexual response. The trials didn't establish an approved treatment.
What changed in the Kisspeptin benefit trials
Trials found four changes that marketers may call Kisspeptin benefits. For women whose periods had stopped, bursts of an ovary-control hormone returned. During fertility treatment, eggs matured while doctors saw no dangerous swelling in the short trial. Men's blood hormones rose. Men and women with low desire showed changes in sexual response.
These findings came from closely watched studies. They don't make Kisspeptin approved care. Nor do they show what would happen at home. The word "benefit" needs that warning beside it. A blood-test rise may matter, but it isn't the same as feeling better. Each section below names both the change and the limit.
What Kisspeptin changed in periods and blood tests
Women whose periods had stopped received Kisspeptin-54 through a vein. Over 8 hours, bursts of the ovary-control hormone happened more often. Each burst released about six times more of that hormone than the placebo drip, which held no drug [5]. The finding suggests their normal hormone timing had restarted. It doesn't prove that every woman's period or fertility would return.
Men in another study received Kisspeptin-10. Within 30 minutes, a testes-control hormone rose. At a higher drip rate, testosterone also rose [3]. Kisspeptin didn't contain testosterone. It prompted the men's bodies to release hormones that led to the increase.
What Kisspeptin did when fertility care risked swollen ovaries
The kisspeptin fertility benefit best supported by trial data is a safer IVF trigger. In a Phase 2 randomized trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) — a potentially serious complication of standard IVF triggers — a single subcutaneous dose of kisspeptin-54 matured eggs in 95% of women with no case of moderate, severe, or critical OHSS, and the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [6]. Because kisspeptin triggers the body's own gentler LH surge rather than a prolonged artificial one, it appears to mature eggs while sidestepping the over-stimulation that drives OHSS. Restoring ovulation in hypothalamic amenorrhea is a second fertility application under study [5]. Both remain investigational, not approved fertility treatments.
Listed for prescription-required care by Promise Peptides (mypromise.com), kisspeptin is considered one patient at a time by a licensed U.S. clinician. A review can finish with no prescription. The service takes U.S. patients only; the state and treatment being considered determine which choices are offered. The compounded preparation has no FDA approval. FDA's safety-risk list still places kisspeptin-10 in Category 2, excluding it from interim 503A compounding discretion.
What Kisspeptin changed in low sexual desire
A trial enrolled 32 men with very low sexual desire. Kisspeptin-54 went into a vein. It changed how their brains responded to sexual sights. Penis swelling rose by up to 56% over placebo, a drip with no drug. The men reported more desire, and doctors saw no harm during the trial [8].
Another trial enrolled 32 women before menopause with the same problem. Kisspeptin-54 changed how their brains handled attraction and sexual dislike. Women more upset by low desire at the start tended to show a larger brain change [9]. These studies measured short responses during watched visits. They didn't prove lasting help for you. Personal accounts carry less weight and appear on the effects page.